Correlation Between Vaccibody and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Vaccibody and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vaccibody and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vaccibody As and Molecular Partners AG, you can compare the effects of market volatilities on Vaccibody and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vaccibody with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vaccibody and Molecular Partners.
Diversification Opportunities for Vaccibody and Molecular Partners
0.07 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Vaccibody and Molecular is 0.07. Overlapping area represents the amount of risk that can be diversified away by holding Vaccibody As and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Vaccibody is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vaccibody As are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Vaccibody i.e., Vaccibody and Molecular Partners go up and down completely randomly.
Pair Corralation between Vaccibody and Molecular Partners
If you would invest 223.00 in Vaccibody As on October 8, 2024 and sell it today you would earn a total of 0.00 from holding Vaccibody As or generate 0.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 5.26% |
Values | Daily Returns |
Vaccibody As vs. Molecular Partners AG
Performance |
Timeline |
Vaccibody As |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Molecular Partners |
Vaccibody and Molecular Partners Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Vaccibody and Molecular Partners
The main advantage of trading using opposite Vaccibody and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vaccibody position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.Vaccibody vs. Molecular Partners AG | Vaccibody vs. MediciNova | Vaccibody vs. Anebulo Pharmaceuticals | Vaccibody vs. Champions Oncology |
Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Stocks Directory Find actively traded stocks across global markets |